drugset / Trial / NCT07071844
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
Phase 2
Not yet recruiting
162 enrolled
GERCOR - Multidisciplinary Oncology Cooperative Group
Servier · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was design to: * To assess the impact of a biweekly (experimental arm) compared to a conventional administration (control arm) on the rate of grade 3-4 neutropenia in metastatic colorectal cancer (mCRC) patients treated with trifluridine/tipiracil plus bevacizumab, and * To identify predictive clinical and biological factors for grade 3-4 neutropenia in this patient population.
Timeline
- Start
- 2025-09
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trifluridine/tipiracil | Unknown | 35 mg/m2 | Oral |
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |